Drug Trial Radar · NCT06666010
PEX010-Assisted Therapy for Stimulant Use Disorder: A Safety, Feasibility and Efficacy Study
Last checked: Nov 20, 2026Latest source record: Oct 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
86
Planned (sponsor's estimate)
Start
Jan 2025
Primary completion
Jan 2028
Study completion Jul 2028
Sponsor
- Lead sponsor
- Filament Health Corp.Industry
- Sponsor type
- Industry
- Collaborators
- University of British Columbia
- First posted
- Oct 30, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if PEX010 is effective for the treatment of Stimulant Use Disorder in adults. The study will also assess the safety and feasibility of administering PEX010 to this population. The main questions it aims to answer are: Does PEX010 reduce stimulant use? What medical problems do participants experience when taking PEX010? Researchers will compare an active PEX010 dose containing 25 mg psilocybin to an active placebo arm, to see if PEX010 works to reduce stimulant use. Participants will: Take PEX010 or the active placebo once during the study, engage in cognitive behavioural therapy, and visit the clinic twice weekly for study intervention and follow-up assessments.
Conditions
- Stimulant Use Disorder
Interventions
PEX010-Assisted TherapyDrug
The investigational medicinal product PEX010, containing 25 mg psilocybin, is a capsule for oral administration that contains the drug substance PYEX.
PEX010(01)Drug
The investigational medicinal product PEX010(01), containing 1 mg psilocybin, is a capsule for oral administration that contains the drug substance PYEX.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in Amphetamine-type Stimulant UseTime frame: 3 Months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.